THE PHARMACOKINETICS OF ONDANSETRON AFTER INTRAVENOUS-INJECTION IN HEALTHY-VOLUNTEERS PHENOTYPED AS POOR OR EXTENSIVE METABOLIZERS OF DEBRISOQUINE

被引：33

作者：

ASHFORTH, EIL ^{[1
]}

PALMER, JL ^{[1
]}

BYE, A ^{[1
]}

BEDDING, A ^{[1
]}

机构：

[1] GLAXO GRP RES LTD,DEPT MED STAT,GREENFORD UB6 0HE,MIDDX,ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 37卷 / 04期

关键词：

ONDANSETRON; PHARMACOKINETICS; CYP2D6;

D O I：

10.1111/j.1365-2125.1994.tb04294.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmacokinetics of the 5-HT3 receptor antagonist ondansetron following an 8 mg i.v. dose were investigated in 12 subjects previously phenotyped with debrisoquine. Six subjects were poor metabolisers (debrisoquine metabolic ratios 29-131) and six were extensive metabolisers (debrisoquine metabolic ratios 0.45-3.4). There was no significant difference in AUC, C(max), CL or t1/2 between the poor and extensive metabolisers. It is concluded that ondansetron clearance is not mediated exclusively by cytochrome P-450 2D6.

引用

页码：389 / 391

页数：3

共 8 条

[1] THE PHARMACOKINETICS OF INTRAVENOUS ONDANSETRON IN PATIENTS WITH HEPATIC IMPAIRMENT [J].

BLAKE, JC ;

PALMER, JL ;

MINTON, NA ;

BURROUGHS, AK .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 35 (04) :441-443

[2] DETERMINATION OF ONDANSETRON IN PLASMA AND ITS PHARMACOKINETICS IN THE YOUNG AND ELDERLY [J].

COLTHUP, PV ;

FELGATE, CC ;

PALMER, JL ;

SCULLY, NL .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (09) :868-871

[3]

de Bruijn K M, 1992, Drugs, V43 Suppl 3, P11

[4] DETERMINATION OF DEBRISOQUINE AND ITS 4-HYDROXY METABOLITE IN BIOLOGICAL-FLUIDS BY GAS-CHROMATOGRAPHY WITH FLAME-IONIZATION AND NITROGEN-SELECTIVE DETECTION [J].

LENNARD, MS ;

SILAS, JH ;

SMITH, AJ ;

TUCKER, GT .

JOURNAL OF CHROMATOGRAPHY, 1977, 133 (01) :161-166

[5]

PABST G, 1960, EUR J CLIN PHARMACOL, V38, P5

[6] AGE AND GENDER EFFECTS ON ONDANSETRON PHARMACOKINETICS - EVALUATION OF HEALTHY AGED VOLUNTEERS [J].

PRITCHARD, JF ;

BRYSON, JC ;

KERNODLE, AE ;

BENEDETTI, TL ;

POWELL, JR .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) :51-55

[7]

SAYNOR DA, 1989, EUR J CANCER CLIN ON, V25, pS75

[8]

TYERS MB, 1989, EUR J CANCER CLIN ON, V25, pS15

← 1 →